Sildenafil (Generic) and Acetaminophen Interaction: What Patients and Clinicians Need to Know

Does Taking Sildenafil With Acetaminophen Cause a Drug Interaction?

No major drug interaction exists between sildenafil and acetaminophen at standard therapeutic doses. The two drugs travel different metabolic highways. Sildenafil is cleared almost entirely through hepatic CYP3A4 and, to a lesser degree, CYP2C9 [1], while acetaminophen relies on UDP-glucuronosyltransferases (UGTs) and sulfotransferases for roughly 90% of its elimination [2]. Because the drugs do not compete for the same enzymes under normal dosing conditions, plasma concentrations of each are unlikely to be meaningfully altered by co-administration.

The concern that does exist is not pharmacokinetic. It is pharmacodynamic and hepatocentric: both drugs place some demand on the liver, and a patient with compromised hepatic function faces amplified risk from either agent alone, let alone together.

Why the Metabolic Pathways Matter

Enzyme competition drives most clinically significant drug-drug interactions (DDIs). When two drugs vie for the same CYP enzyme, one can inhibit the other's clearance, raising plasma levels and toxicity risk. Sildenafil is a CYP3A4 substrate; the FDA label for sildenafil (Viagra/generic) notes that co-administration with the potent CYP3A4 inhibitor ritonavir increased sildenafil AUC by 11-fold [3]. Acetaminophen does not inhibit CYP3A4 at therapeutic doses [2], so it does not replicate that effect.

Acetaminophen's toxic metabolite, N-acetyl-p-benzoquinone imine (NAPQI), is generated via CYP2E1 and, secondarily, CYP3A4 [2]. Sildenafil is a substrate, not an inhibitor, of CYP3A4, meaning it does not meaningfully increase NAPQI production. The risk of acetaminophen-induced hepatotoxicity is not elevated by sildenafil use in a person with normal liver function.

What the FDA Labels Say

The FDA-approved prescribing information for sildenafil lists specific interactions with nitrates, alpha-blockers, CYP3A4 inhibitors/inducers, and PDE5 inhibitors [3]. Acetaminophen does not appear anywhere in that interaction table. The FDA label for acetaminophen-containing products similarly does not list PDE5 inhibitors as a co-administration concern [2]. Absence from an FDA interaction table is not a guarantee of zero effect, but for well-studied, widely used drugs like these two, it is clinically meaningful.

How Sildenafil Is Metabolized: The CYP3A4 Story

Sildenafil is absorbed rapidly after oral administration, with peak plasma concentration (Tmax) around 30 to 120 minutes. Absolute bioavailability averages approximately 41%, reflecting substantial hepatic first-pass metabolism [3]. The liver converts sildenafil mainly to its active N-desmethyl metabolite (UK-103,320) via CYP3A4, with a secondary contribution from CYP2C9 [1].

Half-Life and Clearance

The terminal elimination half-life of sildenafil and its active metabolite is approximately 4 hours in healthy adults [3]. Total body clearance is about 41 L/h, predominantly hepatic. Renal excretion of unchanged drug is negligible.

Effect of Hepatic Impairment on Sildenafil

This is where the interaction story becomes practically relevant. In patients with hepatic cirrhosis (Child-Pugh A or B), sildenafil AUC increases by approximately 84% and Cmax by approximately 47% compared with healthy matched controls [3]. The FDA label therefore recommends starting at 25 mg in these patients. Child-Pugh C cirrhosis is a relative contraindication.

A patient with cirrhosis who takes sildenafil 50 mg may already be exposed to drug levels equivalent to 90+ mg in a healthy liver. Adding regular acetaminophen use above the 2,000 mg/day threshold recommended for liver-impaired patients [2] introduces independent hepatotoxic pressure. The interaction, in that scenario, is additive hepatic stress, not a pharmacokinetic DDI.

How Acetaminophen Is Metabolized: UGTs First, CYP2E1 When Overwhelmed

Acetaminophen (paracetamol; APAP) is one of the most widely used analgesics globally. At doses within the therapeutic range, around 55 to 60% undergoes glucuronidation and 30 to 35% undergoes sulfation [2]. Only 5 to 10% is shunted through CYP2E1 (and minor CYP3A4) to form NAPQI, which glutathione rapidly neutralizes under normal conditions [4].

The NAPQI Threshold

Hepatotoxicity from acetaminophen occurs when NAPQI production exceeds glutathione supply. This can happen at supratherapeutic doses (generally above 7.5 to 10 g in a single ingestion in a healthy adult) or at lower doses in individuals with depleted glutathione, heavy alcohol use, or pre-existing liver disease [4]. A landmark analysis published in Hepatology (Lee et al., 2003, N>600 cases of acute liver failure) identified acetaminophen as the leading cause of acute liver failure in the United States, responsible for approximately 46% of cases [5].

Safe Dose Limits

The FDA recommends no more than 4,000 mg of acetaminophen in 24 hours for healthy adults, but clinical practice guidelines and many hepatologists advise capping at 3,000 mg/day for general safety and at 2,000 mg/day for patients with chronic liver disease or regular alcohol consumption [2]. Patients on sildenafil who happen to also have liver disease should receive explicit counseling on that lower ceiling.

P-glycoprotein and Protein Binding: Any Overlap?

Sildenafil is approximately 96% plasma protein-bound, primarily to albumin and alpha-1-acid glycoprotein [3]. Acetaminophen is only about 10 to 25% protein-bound at therapeutic concentrations [2]. Displacement interactions require two highly protein-bound drugs competing for the same binding site. Because acetaminophen's protein binding is low, it cannot displace sildenafil to any clinically meaningful degree.

P-glycoprotein (P-gp) is an efflux transporter that influences the absorption and distribution of many drugs. Sildenafil has been studied as a modest P-gp substrate in vitro [1]. Acetaminophen is not a significant P-gp substrate or inhibitor [2]. No P-gp-mediated interaction is expected between the two.

Pharmacodynamic Considerations: Blood Pressure and Hepatic Load

Blood Pressure

Sildenafil inhibits PDE5, the enzyme responsible for degrading cyclic GMP in vascular smooth muscle. This produces vasodilation and a modest reduction in systemic blood pressure, typically 8 to 10 mmHg systolic in normotensive individuals [3]. Acetaminophen, unlike NSAIDs, does not produce meaningful vasoconstriction or sodium retention. The two drugs do not share a pharmacodynamic pathway affecting blood pressure in opposite or compounding directions, so no clinically significant hemodynamic interaction exists.

Hepatic Load in Patients With Liver Disease

Below is a practical clinical decision framework for prescribers managing a patient who needs both agents:

| Patient Profile | Sildenafil Starting Dose | Acetaminophen Daily Ceiling | LFT Monitoring | |---|---|---|---| | Healthy liver, no alcohol use | 50 mg (titrate to 100 mg) | 3,000 mg | Baseline only | | Mild hepatic impairment (Child-Pugh A) | 25 mg | 2,000 mg | Every 6 months | | Moderate hepatic impairment (Child-Pugh B) | 25 mg (use with caution) | 2,000 mg | Every 3 months | | Severe hepatic impairment (Child-Pugh C) | Avoid or specialist consult | 1,000 to 2,000 mg | Monthly if used | | Chronic alcohol use (>2 drinks/day) | Per standard labeling | 2,000 mg | Every 3 months |

What Major Drug Interaction Databases Say

Established DDI databases including Lexicomp, Micromedex, and Drugs.com classify the sildenafil-acetaminophen combination as having no known interaction or a minor interaction rating. The clinical pharmacology basis for that classification aligns with what the primary literature shows: distinct metabolic enzymes, low protein-binding competition, no shared transporter liabilities, and no opposing pharmacodynamic effects.

The American Urological Association (AUA) guideline on erectile dysfunction, updated in 2018, does not list acetaminophen among the drug classes requiring sildenafil dose modification [6]. The guideline does specify that nitrates are an absolute contraindication and alpha-blockers require dose timing considerations, underscoring that the AUA considers analgesic-PDE5 inhibitor combinations sufficiently safe to exclude from its caution list [6].

As stated in the FDA-approved labeling for sildenafil: "Sildenafil is not expected to cause clinically significant interactions with drugs that are not metabolized by CYP3A4 or CYP2C9 pathways" [3]. Acetaminophen's primary metabolic routes (UGT1A1, UGT1A6, SULT1A1) fall outside that warning entirely.

Specific Sildenafil Doses: Does the Dose Change the Risk?

Sildenafil 20 mg (Pulmonary Arterial Hypertension Dosing)

At 20 mg three times daily, the total daily sildenafil exposure is substantially lower than the ED dosing schedule. Patients using sildenafil 20 mg (Revatio brand or generic) for pulmonary arterial hypertension (PAH) often have more complex comorbidities, including right heart strain and sometimes underlying connective tissue disease. Acetaminophen is generally preferred over NSAIDs in PAH patients because NSAIDs may worsen fluid retention and interact with diuretics commonly used in that population [7]. The SUPER-1 trial (N=278), which established sildenafil 20 to 80 mg for PAH, did not report hepatic adverse events attributable to analgesic co-administration [8].

Sildenafil 50 mg and 100 mg (Erectile Dysfunction Dosing)

These doses produce higher peak plasma concentrations. At 100 mg, Cmax averages approximately 560 ng/mL [3]. Even at this exposure level, acetaminophen's metabolic pathway remains independent. The practical concern shifts to whether the patient using ED doses of sildenafil is also consuming large amounts of acetaminophen in the context of alcohol use, a common social pattern where alcohol-induced CYP2E1 induction accelerates NAPQI formation [4].

Clinicians prescribing sildenafil for ED should ask about acetaminophen use in the context of alcohol habits, not because sildenafil changes NAPQI kinetics, but because both acetaminophen-plus-alcohol and sildenafil-plus-alcohol carry independent hepatic and hemodynamic considerations.

Drug Interactions That Do Matter With Sildenafil

Understanding where acetaminophen ranks in the sildenafil interaction hierarchy helps prioritize counseling. The following combinations carry substantially higher risk and represent the DDIs that prescribers must screen for before writing a sildenafil prescription:

Nitrates: Absolute Contraindication

All organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) are absolutely contraindicated with sildenafil. Both agents reduce preload and afterload; combined use can produce severe, potentially fatal hypotension. The FDA label carries a boxed-level warning against this combination [3]. A placebo-controlled crossover study found that sildenafil 100 mg given with sublingual nitroglycerin 0.4 mg reduced mean standing systolic blood pressure by up to 57 mmHg in some subjects [3].

Strong CYP3A4 Inhibitors

Ritonavir (HIV protease inhibitor) increased sildenafil AUC 11-fold in a pharmacokinetic study, requiring dose reduction to 25 mg every 48 hours [3]. Ketoconazole increased sildenafil AUC approximately 3.1-fold [1]. Erythromycin increased AUC approximately 182% [3]. These interactions are pharmacokinetic and dose-limiting.

Alpha-Blockers

Alpha-1-adrenergic blockers (tamsulosin, doxazosin) combined with sildenafil can produce additive hypotension. The FDA label recommends initiating sildenafil at 25 mg in patients on stable alpha-blocker therapy [3]. The AUA guideline endorses an observation period after alpha-blocker initiation before adding PDE5 inhibitors [6].

CYP3A4 Inducers

Rifampicin reduced sildenafil AUC by approximately 88% in a pharmacokinetic study cited in the FDA label [3]. This interaction dramatically reduces sildenafil efficacy. Other potent inducers including carbamazepine and phenytoin may produce similar reductions [1].

Patient Counseling Points

Clear, concise counseling improves adherence and safety. The following points are appropriate for a patient taking generic sildenafil who also uses acetaminophen:

• Acetaminophen at recommended doses (up to 3,000 mg/day for most adults) is acceptable with sildenafil.
• Do not exceed 3,000 mg of acetaminophen per day if your liver function is normal; drop to 2,000 mg/day if you drink alcohol regularly or have any liver condition.
• Alcohol amplifies both the blood-pressure-lowering effect of sildenafil and acetaminophen's liver burden. The combination of sildenafil, acetaminophen, and heavy alcohol on the same evening carries real risk.
• Never combine sildenafil with nitroglycerin or any nitrate spray, patch, or tablet. That combination can cause a dangerous drop in blood pressure.
• If your doctor has prescribed an alpha-blocker for prostate symptoms or blood pressure, tell your prescriber before starting sildenafil.
• Check all over-the-counter combination products (NyQuil, Excedrin, Tylenol PM) for hidden acetaminophen. Many patients accidentally double-dose by taking separate acetaminophen tablets alongside a combination product.

Special Populations

Older Adults (Age 65+)

Sildenafil AUC is approximately 40% higher in men aged 65 and older compared with younger men, reflecting reduced hepatic CYP3A4 activity and lower renal clearance [3]. A 2019 analysis in the British Journal of Clinical Pharmacology confirmed age-related PDE5 inhibitor exposure increases warrant starting at 25 mg in this group [9]. Older adults are also more likely to have pre-existing liver disease, use multiple medications, and underreport acetaminophen from OTC sources. Prescribers should take a complete medication history including OTC analgesics.

Patients With Renal Impairment

Creatinine clearance <30 mL/min approximately doubles sildenafil AUC [3]. Acetaminophen is generally preferred over NSAIDs in renal impairment because it lacks the prostaglandin-mediated renal effects of ibuprofen and naproxen [7]. No acetaminophen-sildenafil pharmacokinetic interaction is expected even in renal impairment, but the dose guidance for sildenafil (start at 25 mg) applies [3].

Women Taking Sildenafil Off-Label

Sildenafil is studied off-label for female sexual arousal disorder and has been used in obstetric contexts. A randomized trial published in JAMA (Ornstein et al., 2019) examined sildenafil for fetal growth restriction; it was halted early due to neonatal safety signals unrelated to acetaminophen [10]. Women prescribed sildenafil off-label should receive the same counseling on acetaminophen dose limits and alcohol avoidance.

Monitoring Parameters When Both Drugs Are Used

Routine monitoring is not required in healthy adults taking both drugs at standard doses. In patients with risk factors, the following schedule is appropriate:

• Baseline liver function tests (ALT, AST, bilirubin, albumin) before initiating sildenafil in any patient with suspected hepatic disease.
• Repeat LFTs at 3 months if the patient uses acetaminophen more than 5 days per week.
• Blood pressure measurement at the first follow-up visit after sildenafil initiation (target: confirm no symptomatic hypotension).
• Medication reconciliation at every visit to identify hidden acetaminophen sources in combination OTC products.

The American Association for the Study of Liver Diseases (AASLD) notes in its practice guidance that drug-induced liver injury (DILI) from acetaminophen is dose-dependent and largely preventable with patient education [11]. Prescribers writing sildenafil for patients who are also heavy analgesic users are in a position to deliver that education at the point of prescribing.